634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster II

Phase II study of reparixin in patients with myelofibrosis myeloproliferative neoplasms research consortium MPN RC 120 trial

Trial in progress Efficacy and safety of givinostat versus hydroxyurea in patients with polycythemia vera GIV IN PV

Trial in progress a randomized study of ASTX727 with or without Iadademstat in accelerated blast phase myeloproliferative neoplasms

Trends in second primary malignancies in myelofibrosis pre and post JAK inhibitor era A surveillance epidemiology and end Results database study

The prognostic value of JAK2V617F burden for discontinuation of interferon α2 in patients with myeloproliferative neoplasms

Myeloproliferative neoplasm thrombosis risk characterized by MerTK biomarker

It s not yet time to abandon ruxolitinib in anemic myelofibrosis Predictive factors of erythroid response to standard anemia directed therapies combined with ruxolitinib

Rapid JAK2 V617F decline predicts response durability Kinetics of JAK2 V617F in ropeginterferon alfa 2b treated polycythemia vera

Evaluation of low intensity treatment strategies and outcomes in patients with accelerated Phase and blast Phase myeloproliferative neoplasms A hero consortium study

Establishment of differential diagnostic model for ET and pre PMF based on circulating CD34 cells and its clinical significance

Not so exclusive Co mutations in JAK2 MPL and CALR define distinct hematologic and clonal signatures

The combination of ruxolitinib and the CDK4 6 inhibitor abemaciclib demonstrates safety and efficacy in previously treated myelofibrosis patients Results of A phase I study

Clinical molecular and demographic features of systemic mastocytosis Analysis of a large cohort

Mapping out the impact of MAP kinase in primary myelofibrosis

Real world characteristics and treatment patterns in patients with essential thrombocythemia by thrombosis risk levels

Long term rusfertide treatment in polycythemia vera Initial results from the phase 2 THRIVE extension study

Impact of new or worsening anemia and thrombocytopenia on clinical outcomes in JAK inhibitor–naive myelofibrosis patients treated with ruxolitinib

Molecular predictors of anemia response to momelotinib in patients with myelofibrosis Real world outcomes from the momgemfin study

Refining thrombotic risk stratification in essential thrombocythemia Impact of european leukemia net clinical signs and symptoms in patients treated with hydroxyurea

Prognostic impact of persistent and treatment emergent cytopenia in 879 myelofibrosis patients treated with ruxolitinib The RUX MF study

Fedratinib in combination with CC 486 an oral hypomethylating agent in patients with accelerated phase myelofibrosis Results from the phase I II famy trial

Preliminary experience from the ODYSSEY trial Efficacy and safety of momelotinib in combination with luspatercept in patients with transfusion dependent myelofibrosis

Clinical and molecular predictors of interferon α response in erdheim chester disease and myeloproliferative neoplasm

Disease stage specific mutational landscape in essential thrombocythemia and prognostic correlates A Mayo Clinic study of 500 NGS informative cases

Clinical NGS detection of TP53 mutations in chronic phase primary myelofibrosis Comparative analyses of genotype and prognosis

Trial in progress A study of roginolisib in combination with ruxolitinib in patients with myelofibrosis who are unresponsive to JAK inhibitors HEMA MED

The activin receptor like kinase 2 inhibitor zilurgisertib INCB000928 as monotherapy or with ruxolitinib in patients with anemia due to myelofibrosis Phase 1 2 study final results

The transition from CHIP to overt myeloproliferative neoplasms A 13 year longitudinal study of JAK2 positive citizens

Risk of second primary malignancies and leukemic transformation in patients with Philadelphia chromosome negative myeloproliferative neoplasms A population level US retrospective cohort study